Meeting
2022 ASCO Genitourinary Cancers Symposium
Genomic characterization of patients (pts) with de-novo high-volume metastatic castration-sensitive prostate cancer (dn-hv-mCSPC) compared to those without dn-hv-mCSPC.
Authors
Nicolas Sayegh
Huntsman Cancer Institute-University of Utah Health Care, Salt Lake City, UT
Nicolas Sayegh , Yeonjung Jo , Nishita Tripathi , Taylor Ryan McFarland , Adam Kessel , Roberto Nussenzveig , Beverly Chigarira , Haoran Li , Clara Tandar , Kamal Kant Sahu , Benjamin Haaland , Benjamin L. Maughan , Umang Swami , Neeraj Agarwal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Other
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 186)
DOI
10.1200/JCO.2022.40.6_suppl.186
Abstract #
186
Poster Bd #
K4
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Genomic aberrations associated with overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) or placebo (PBO) plus androgen deprivation therapy (ADT) in TITAN.
First Author: Neeraj Agarwal
Poster
2019 Genitourinary Cancers Symposium
Genomic findings in adenocarcinoma of the urinary bladder.
First Author: Oleg Shapiro
Poster
2018 ASCO Annual Meeting
Genomic profiling of primary prostate tumors from patients who develop metastatic castration-resistant prostate cancer (mCRPC).
First Author: Joaquin Mateo
Poster
2020 Genitourinary Cancers Symposium
Circulating tumor cell (CTC) genomic signatures of hormone therapy resistance in men with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Santosh Gupta